Hypothesis
Version 1
Preserved in Portico This version is not peer-reviewed
Prediction of Potential 3CLpro-Targeting Anti-SARS-CoV-2 Compounds from Chinese Medicine
Version 1
: Received: 14 March 2020 / Approved: 15 March 2020 / Online: 15 March 2020 (15:11:22 CET)
How to cite: Sun, N.; Wong, W.; Guo, J. Prediction of Potential 3CLpro-Targeting Anti-SARS-CoV-2 Compounds from Chinese Medicine. Preprints 2020, 2020030247 (doi: 10.20944/preprints202003.0247.v1). Sun, N.; Wong, W.; Guo, J. Prediction of Potential 3CLpro-Targeting Anti-SARS-CoV-2 Compounds from Chinese Medicine. Preprints 2020, 2020030247 (doi: 10.20944/preprints202003.0247.v1).
Abstract
The recent outbreak of coronavirus disease 2019 caused by the new coronavirus, SARS-CoV-2, has become an international emergency. Since there is no effective therapy for the treatment of this disease, drugs or vaccine that can prevent or cure the SARS-CoV-2 infection are urgently needed. The viral 3-chymotrypsin-like cysteine protease (3CLpro), which plays a key role in the replication of coronavirus, is a potential drug target for the development of anti-SARS-CoV-2 drugs. With the crystal structure of 3CLpro, we performed virtual screening from a small chemical library of a Traditional Chinese Medicine recipe- FuFang Zhenzhu Tiaozhi (FTZ). Five compounds with the best scores were screened and could be considered as potential hit compounds to be investigated further with bioassays for their anti-virus effects.
Keywords
SARS-CoV-2; COVID-19; molecular docking; Chinese medicine; lithospermic acid B; specnuezhenide; neonuezhenide; rutin; neodiosmin
Subject
MEDICINE & PHARMACOLOGY, Other
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.
Leave a public commentSend a private comment to the author(s)

